Table 1. Patient characteristics by treatment regimen.
| EC-DT | EC-DL | |
|---|---|---|
| Characteristics | n =50 | n =52 |
|
Age, median (range) |
48.5 (32–74) |
48 (30–79) |
|
ECOG PS, n (%) | ||
| 0 | 46 (92.0) | 47 (90.4) |
| 1 |
4 (8.0) |
5 (9.6) |
|
Menopausal status, n (%) | ||
| Premenopausal | 29 (58.0) | 28 (53.9) |
| Postmenopausal |
21 (42.0) |
24 (46.1) |
|
Estrogen receptor | ||
| Positive | 30 (60.0) | 29 (55.8) |
| Negative |
20 (40.0) |
23 (44.2) |
|
Progesterone receptor | ||
| Positive | 21 (42.0) | 24 (46.2) |
| Negative |
29 (58.0) |
28 (53.8) |
|
Estrogen receptor/progesterone receptor | ||
| ER+/PR+ | 21 (42.0) | 22 (42.3) |
| ER+/PR- |
9 (18.0) |
7 (13.5) |
|
Histologic type, n (%) | ||
| Ductal | 48 (96.0) | 48 (92.3) |
| Lobular | 0 (0.0) | 1 (1.9) |
| Other |
2 (4.0) |
3 (5.8) |
|
Tumor grade, n (%) | ||
| 1 | 5 (10.0) | 2 (3.8) |
| 2 | 15 (30.0) | 17 (32.7) |
| 3 | 22 (44.0) | 25 (48.1) |
| Unknown |
8 (16.0) |
8 (15.4) |
|
Tumour size, n (%) | ||
| T1 | 6 (12.0) | 8 (15.4) |
| T2 | 31 (62.0) | 29 (55.8) |
| T3 | 4 (8.0) | 8 (15.4) |
| T4 | 9 (18.0) | 7 (13.4) |
| Median tumour size, cm (range) |
3.3 (1.0–10.0) |
3.5 (1.0–15.8) |
|
Nodal status, n (%) | ||
| N0 | 13 (26.0) | 19 (36.5) |
| N1 | 35 (70.0) | 32 (61.6) |
| N2 | 2 (4.0) | 1 (1.9) |
Abbreviations: EC-DL=epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel plus lapatinib; EC-DT=epirubicin plus cyclophosphamide x 4 cycles followed by docetaxel plus trastuzumab; ECOG=Eastern Cooperative Oncology Group.